The Road to Commercial-Scale iPSC Cell Therapy
Can iPSC platforms deliver consistent, commercial-scale cell therapies for large patient populations?
-
1
Induced pluripotent stem cell (iPSC) therapies are gaining traction as off-the-shelf solutions, moving beyond patient-specific approaches.
-
2
Japan has granted provisional market entrance for iPSC-based cardiac and Parkinson's disease products, indicating progress in the field.
-
3
Key challenges in iPSC therapy include biological control and the complexity of scaling production processes for consistent outcomes.
-
4
Manufacturers must integrate process development with clinical strategies early to ensure scalability and industrial viability of cell lines.
-
5
Reducing the cost of goods, particularly for raw materials, is essential for making allogeneic cell therapies accessible globally.
